Home Markets Earnings Estimate Forecast on Idera Pharmaceuticals, Inc.(IDRA)

Earnings Estimate Forecast on Idera Pharmaceuticals, Inc.(IDRA)


Idera Pharmaceuticals, Inc.(IDRA): For the most recent quarter end, Idera Pharmaceuticals, Inc. reported Annual Earnings of $-0.1. Based on the filings, last years Annual Earnings was, $-0.42. For the most recent quarter end, IDRA reported a surprise Earnings per Share of 9.09% . The consensus estimate for current quarter is $-0.11 and for the current fiscal year, the estimate is $-0.42. For the Next fiscal year, the estimate is $-0.41 based on the consensus. Cambridge based Idera Pharmaceuticals, Inc. Last reported the Quarter results on Dec 31, 2016 and the Next earnings date is scheduled to be released on Mar 09, 2017.

Idera Pharmaceuticals, Inc. has received $-0.11 as the consensus Earnings Estimate for the Quarter ending on Dec 2016 ,According to the estimate provided by 3 Financial Advisor in the Stock Trading Firms. Among 3 Analysts, Bottom line EPS Estimate for the current quarter is $-0.13 while the top line estimate is $-0.09 , a key information to consider for Day Trading and investing in stocks. The EPS growth rate is projected at -6.67%. Idera Pharmaceuticals, Inc. reported better than expected with a surprise EPS of 9.09% or $0.01 during its most recent quarterly earnings. The Actual EPS was $-0.1 compared to the Estimated EPS of $-0.11. According to the corporate earnings calendar, Idera Pharmaceuticals, Inc. will release next earnings on Mar 09, 2017 with an estimated EPS consensus of $-0.11. Based on the consensus of stock financial advisors the stock has a price target of $5. Current year estimate on EPS consensus is $-0.42.

For Dividend Investing Stock Market Traders Idera Pharmaceuticals, Inc. has a Dividend Yield of 0% with an Annual Dividend of $0.

Company has reported several Insider transactions to the SEC, on Oct 5, 2016, Youssef El Zein (director 10% owner) purchased 4,228 shares at 2.56 per share price.On Oct 5, 2016, Maxine Gowen (director) purchased 4,102 shares at 2.56 per share price.On May 13, 2016, Mark J Casey (Senior VP & General Counsel) purchased 34,450 shares at 1.44 per share price.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) rose 1.2% or 0.02 points on Wednesday and made its way into the gainers of the day. After trading began at $1.65 the stock was seen hitting $1.73 as a peak level and $1.64 as the lowest level. The stock ended up at $1.68. The daily volume was measured at 808,221 shares. The 52-week high of the share price is $3.33 and the 52-week low is $1.19. The company has a market cap of $248 million.

Idera Pharmaceuticals, Inc. is a drug discovery and development company that is developing drug candidates to treat cancer and infectious, respiratory, and autoimmune diseases, and for use in combination with therapeutic and prophylactic vaccines. Ideras proprietary drug candidates are designed to modulate Toll-like Receptors, the bodys first line of immune defense. Ideras pioneering DNA chemistry expertise enables it to identify drug candidates for internal development and creates opportunities for multiple collaborative alliances.



Please enter your comment!
Please enter your name here